MAPT and Alzheimer disease: This is obvious from the report that upon DR (40% restriction), the triple transgenic mouse model of AD (3XTgAD) showed reduced levels of Aβ1–40, Aβ1–42 and phosphorylated tau compared to control mice (fed ad libitum) at 17 months age while no such reduction was observed in 3XTgAD mice fed intermittently (food deprivation for 24 h every second day)75.